These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20533106)

  • 1. Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia.
    Erçin CN; Uygun A; Toros AB; Kantarcioğlu M; Kilciler G; Polat Z; Bağci S
    Turk J Gastroenterol; 2010 Mar; 21(1):12-6. PubMed ID: 20533106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication.
    Zullo A; Hassan C; De Francesco V; Lorenzetti R; Marignani M; Angeletti S; Ierardi E; Morini S
    Dig Liver Dis; 2003 Apr; 35(4):232-6. PubMed ID: 12801033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori.
    Uygun A; Kadayifçi A; Yeşilova Z; Savaş MC; Ateş Y; Karslioğlu Y; Ciğerim M; Bağci S; Dağalp K
    Turk J Gastroenterol; 2004 Dec; 15(4):219-24. PubMed ID: 16249974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
    Wong WM; Gu Q; Chu KM; Yee YK; Fung FM; Tong TS; Chan AO; Lai KC; Chan CK; Wong BC
    Aliment Pharmacol Ther; 2006 Feb; 23(3):421-7. PubMed ID: 16423001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication].
    Jung HS; Shim KN; Baik SJ; Na YJ; Kang MJ; Jung JM; Ha CY; Jung SA; Yoo K
    Korean J Gastroenterol; 2008 May; 51(5):285-90. PubMed ID: 18516012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment.
    Bosques-Padilla FJ; Garza-González E; Calderón-Lozano IE; Reed-SanRoman G; de Ariño Suárez M; Valdovinos-Díaz MA; Orozco-Gámiz A; Blancas-Valencia JM; Tamayo-de la Cuesta JL
    Helicobacter; 2004 Oct; 9(5):417-21. PubMed ID: 15361080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial.
    Chung JW; Jung YK; Kim YJ; Kwon KA; Kim JH; Lee JJ; Lee SM; Hahm KB; Lee SM; Jeong JY; Yun SC
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1675-80. PubMed ID: 22849546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.
    Di Caro S; Franceschi F; Mariani A; Thompson F; Raimondo D; Masci E; Testoni A; La Rocca E; Gasbarrini A
    Dig Liver Dis; 2009 Jul; 41(7):480-5. PubMed ID: 18974025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
    Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
    J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
    Avşar E; Tiftikçi A; Poturoğlu S; Erzin Y; Kocakaya O; Dinçer D; Yıldırım B; Güliter S; Türkay C; Yılmaz U; Onuk MD; Bölükbaş C; Ellidokuz E; Bektaş A; Taşan G; Aytuğ N; Ateş Y; Kaymakoğlu S
    Turk J Gastroenterol; 2013; 24(4):316-21. PubMed ID: 24254262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
    Güliter S; Keleş H; Ozkurt ZN; Cengiz DU; Kolukisa E
    Turk J Gastroenterol; 2005 Mar; 16(1):29-33. PubMed ID: 16252185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication.
    Eisig JN; Silva FM; Barbuti RC; Rodriguez TN; Malfertheiner P; Moraes Filho JP; Zaterka S
    BMC Gastroenterol; 2009 May; 9():38. PubMed ID: 19470177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
    Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
    Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of levofloxacin-based triple therapy for first-line helicobacter pylori eradication.
    Telaku S; Manxhuka-Kerliu S; Kraja B; Qirjako G; Prifti S; Fejza H
    Med Arch; 2013; 67(5):348-50. PubMed ID: 24601169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
    Zheng Q; Pan Y; Zhang L; Xiao SD
    Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole.
    Marzio L; Coraggio D; Capodicasa S; Grossi L; Cappello G
    Helicobacter; 2006 Aug; 11(4):237-42. PubMed ID: 16882326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy.
    Rakici H; Ayaz T; Akdogan RA; Bedir R
    Digestion; 2014; 90(4):261-4. PubMed ID: 25547786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia.
    De Francesco V; Della Valle N; Stoppino V; Amoruso A; Muscatiello N; Panella C; Ierardi E
    Aliment Pharmacol Ther; 2004 May; 19(9):993-8. PubMed ID: 15113366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori.
    Polat Z; Kadayifci A; Kantarcioglu M; Ozcan A; Emer O; Uygun A
    Eur J Intern Med; 2012 Mar; 23(2):165-8. PubMed ID: 22284248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
    Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
    Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.